Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Katherine P. Sugarman"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9886acbf57f0bc41d9f3c6a77325893b
https://doi.org/10.1200/jco.22.02544
https://doi.org/10.1200/jco.22.02544
Autor:
Thomas Brodowicz, Frank V. Fossella, Frances A. Shepherd, Giorgio V. Scagliotti, Christian Manegold, Christoph C. Zielinski, Lorinda Simms, Katherine P. Sugarman, Johan Vansteenkiste, Chandra P. Belani
Publikováno v:
Journal of Thoracic Oncology. 6(1):64-70
Introduction: Recently, histology has emerged as a predictive factor for pemetrexed efficacy in non-small cell lung cancer (NSCLC). These analyses evaluate whether the differential efficacy of pemetrexed by NSCLC histology is reproducible and consist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46dbe1aa84c817df5001a1c7cf108195
Autor:
Joshua Nyambose, David M. Thompson, KM Clements, Craig C. Earle, Martin D. Marciniak, Gerson Peltz, Kathleen Lang, Douglas E. Faries, Douglas C.A. Taylor, Katherine P. Sugarman
Publikováno v:
Chemotherapy Research and Practice
Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients (N=2,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1948b043c56082a8e5913128548a4eb1
https://doi.org/10.1155/2010/524629
https://doi.org/10.1155/2010/524629
Autor:
Christoph C. Zielinski, Maciej Krzakowski, Katherine P. Sugarman, Joo Hang Kim, Thomas Brodowicz, Sung Hyun Yang, Patrick Peterson, E. Laack, Isabel Bover, Chandra P. Belani, Yi-Long Wu, Stephen Begbie, Valentina Tzekova, K. Krejcy, Jayaprakash Madhavan, José Rodrigues Pereira, William J. John, Tudor Ciuleanu, Branka Cucevic
Publikováno v:
The Lancet. 374:1432-1440
Summary Background Several studies have shown the efficacy, tolerability, and ease of administration of pemetrexed—an antifolate antineoplastic agent—in patients with advanced non-small-cell lung cancer. We assessed pemetrexed as maintenance ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c0ae8eb43c9c378e63964382e9dcb00
https://doi.org/10.1016/s0140-6736(09)61497-5
https://doi.org/10.1016/s0140-6736(09)61497-5
Autor:
Renato G. Martins, Carla Visseren-Grul, Katherine P. Sugarman, Purvish M. Parikh, Lorinda Simms, Christian Manegold, Johan Vansteenkiste, Kostas N. Syrigos, J. von Pawel, G.V. Scagliotti
Background Baseline patient and disease characteristics are investigated in non-small-cell lung cancer (NSCLC) in an effort to predict response to treatment and optimize patients’ outcomes. Histology has recently been identified in multiple NSCLC p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d285342b9e0ef89452cd162a9840cac8
http://hdl.handle.net/2318/65546
http://hdl.handle.net/2318/65546
Autor:
Patrick Peterson, Giorgio V. Scagliotti, Nasser H. Hanna, Frank V. Fossella, J. Blatter, Frances A. Shepherd, Katherine P. Sugarman, Lorinda Simms
Background. Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc3e459abc055decb457aac64d584704
http://hdl.handle.net/2318/61724
http://hdl.handle.net/2318/61724
Publikováno v:
Annals of Oncology. 21:1731-1732
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac3976dd6412431d4167cda016a1e93f
https://doi.org/10.1093/annonc/mdq327
https://doi.org/10.1093/annonc/mdq327
Publikováno v:
Journal of Clinical Oncology. 26:5651-5652
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f901fa2de958913249098eb39371f31c
https://doi.org/10.1200/jco.2008.19.5560
https://doi.org/10.1200/jco.2008.19.5560
Autor:
Douglas C.A. Taylor, Craig C. Earle, J. Nyambose, Martin D. Marciniak, KM Clements, Douglas E. Faries, Kathleen Lang, Katherine P. Sugarman
Publikováno v:
Journal of Clinical Oncology. 26:19067-19067
19067 Background: Data regarding the impact of tumor histology on survival in patients receiving chemotherapy treatment for advanced-staged NSCLC is lacking. The purpose of this analysis was to ass...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d63e149cb3786c021e24c2547f02e4d
https://doi.org/10.1200/jco.2008.26.15_suppl.19067
https://doi.org/10.1200/jco.2008.26.15_suppl.19067
Autor:
Giorgio V. Scagliotti, Bonne Biesma, Joachim von Pawel, Katherine P. Sugarman, Parikh Purvish, Coleman K. Obasaju, Johan Vansteenkiste, Lorinda Simms, J. Blatter, Christian Manegold
Publikováno v:
Journal of Thoracic Oncology. 2:S306
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f15dbfdb1083d67956b8e49dc765ec99
https://doi.org/10.1097/01.jto.0000283088.78970.9b
https://doi.org/10.1097/01.jto.0000283088.78970.9b